These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6203147)
1. Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages. De Lena M; Villa S; Di Fronzo G Recent Results Cancer Res; 1984; 91():243-7. PubMed ID: 6203147 [No Abstract] [Full Text] [Related]
2. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy]. Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397 [No Abstract] [Full Text] [Related]
3. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer. Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248 [TBL] [Abstract][Full Text] [Related]
4. [Value of hormone therapy in metastasizing breast cancer]. Samonigg H Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer. Namer M; Milano G; Khater R; Frenay M; Thyss A; Renée N Breast Cancer Res Treat; 1986; 8(2):161-3. PubMed ID: 2949788 [No Abstract] [Full Text] [Related]
6. [Hormonal control of disseminated breast cancer]. Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu Sov Med; 1990; (6):94-7. PubMed ID: 2144368 [No Abstract] [Full Text] [Related]
7. The effects of sequential treatment with ethynyloestradiol and medroxyprogesterone acetate on oestrogen and progestogen receptors in breast cancer. Ghilchik M; Shaikh NA; Beranek PA; Reed MJ; Braunsberg H J Steroid Biochem; 1989; 34(1-6):403-5. PubMed ID: 2533948 [TBL] [Abstract][Full Text] [Related]
8. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Hortobagyi GN; Buzdar AU; Frye D; Yap HY; Hug V; Pinnamaneni K; Fraschini G; Halvorson HC; Blumenschein GR Breast Cancer Res Treat; 1985; 5(3):321-6. PubMed ID: 3161565 [TBL] [Abstract][Full Text] [Related]
9. [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study]. Wander HE; Kleeberg UR; Gärtner E; Hartlapp J; Scherpe A; Bönisch E; Nagel GA Onkologie; 1987 Apr; 10(2):104-6. PubMed ID: 2954006 [No Abstract] [Full Text] [Related]
10. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer]. Dryzhak VI Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239 [No Abstract] [Full Text] [Related]
11. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study]. Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938 [No Abstract] [Full Text] [Related]
12. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Petru E; Schmähl D Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170 [TBL] [Abstract][Full Text] [Related]
13. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results. Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248 [TBL] [Abstract][Full Text] [Related]
15. [Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer]. Doihara H; Takashima S; Saeki H; Takiyama W; Kurita A; Soga H; Tanada M; Yokoyama N; Moriwaki S Gan To Kagaku Ryoho; 1990 Oct; 17(10):2057-62. PubMed ID: 2145805 [TBL] [Abstract][Full Text] [Related]
16. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate]. Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889 [TBL] [Abstract][Full Text] [Related]
17. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy]. Tominaga T Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307 [TBL] [Abstract][Full Text] [Related]
18. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system]. Schenk H; Fereberger W MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871 [No Abstract] [Full Text] [Related]
19. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration]. Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599 [TBL] [Abstract][Full Text] [Related]
20. Progestational agents in advanced breast cancer: an overview. Haller DG; Glick JH Semin Oncol; 1986 Dec; 13(4 Suppl 4):2-8. PubMed ID: 3026051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]